Bioelectronic materials and devices for smart drug delivery (BioEMat)

用于智能药物输送的生物电子材料和设备（BioEMat）

• 批准号: EP/Y008529/1
• 负责人: Christopher Proctor
• 金额: $ 251.39万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY008529%2F1
• 关键词: Bioelectronic; materials; devices; smart; drug

Millions of people suffer from neurological disorders for which there are few, if any, viable treatment options. Meanwhile, many promising drugs designed to treat neurological disorders fail in late-stage testing because of the inability to reach the desired target within the brain and/or due to interactions with healthy regions that cause serious side effects. I have developed an innovation solution to these problems: a minimally invasive bioelectronic device that can electrophoretically deliver drugs when and where they are needed. My most recent research demonstrated that such a device can prevent seizures by delivering inhibitory neural transmitters to the seizure source. These results have evoked visions of a platform technology for personalized medicine that could revolutionize treatment for neurological disorders, including epilepsy. However, there are significant challenges related to materials and device engineering that require further break-throughs for this technology to reach its full potential. These challenges include overcoming electrode capacitance limitations, engineering implants to respond to biomarkers of disease, and realizing long termtissue compliance and efficacy of drug delivery. I will leverage my extensive experience with state-of-the-art materials, devices and neurological applications to take a multi-faceted, interdisciplinary approach to overcoming these critical challenges. The research plan will comprise developing new bioelectronic materials and device concepts and validating them in disease models for epilepsy - a disorder for which 30% of patients do not respond to conventional drug treatments. Altogether these efforts will accelerate electronically controlled drug delivery devices towards large-scale implementation in the clinic to the benefit of the many who are afflicted with intractable neurological disorders.

数以百万计的人患有神经系统疾病，几乎没有可行的治疗选择。与此同时，许多有希望治疗神经疾病的药物在后期测试中失败，原因是无法在大脑内达到预期的目标，和/或由于与健康区域的相互作用会导致严重的副作用。我已经为这些问题开发了一种创新的解决方案：一种微创的生物电子设备，可以在需要的时候随时随地电泳法输送药物。我最近的研究表明，这种设备可以通过向癫痫发作源传递抑制性神经递质来防止癫痫发作。这些结果唤起了人们对个性化药物平台技术的憧憬，这可能会彻底改变包括癫痫在内的神经疾病的治疗。然而，与材料和设备工程相关的重大挑战需要进一步突破，才能充分发挥这项技术的潜力。这些挑战包括克服电极电容限制，设计植入物以响应疾病的生物标志物，以及实现长期的组织顺应性和药物输送的有效性。我将利用我在最先进的材料、设备和神经学应用方面的丰富经验，采取多方面、跨学科的方法来克服这些关键挑战。研究计划将包括开发新的生物电子材料和设备概念，并在癫痫的疾病模型中验证它们。癫痫是一种疾病，30%的患者对传统药物治疗没有反应。总之，这些努力将加速电子控制药物输送装置在临床上的大规模实施，使许多患有顽固性神经疾病的人受益。